Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Activated CIK + CD3-MUC1 bispecific antibody
- Development stage
- Unknown
- Lead developer
- Fuda Cancer Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This investigational cell-based immunotherapy is being developed by Fuda Cancer Hospital in Guangzhou, China, for the treatment of MUC1-positive advanced breast cancer. The therapy utilizes cytokine-induced killer (CIK) cells—a heterogeneous population of immune effector cells dominated by CD3+CD56+ natural killer-like T lymphocytes—that are "armed" with a bispecific antibody. This bispecific antibody simultaneously targets the CD3 receptor on T cells and the Mucin 1 (MUC1) antigen, a tumor-associated glycoprotein that is frequently overexpressed and abnormally glycosylated in epithelial malignancies. By bridging the effector CIK cells to MUC1-expressing tumor cells, the therapy facilitates targeted cytotoxic activity. In clinical investigation, the CIK cells are further activated using a PD-1 inhibitor to enhance their anti-tumor efficacy. This approach is currently being evaluated in Phase II clinical trials in combination with cryotherapy.
- Other names
- Activated CIK armed with anti-CD3-MUC1 bispecific antibodyTarget Activated CIKanti-CD3-MUC1 bispecific antibody-armed CIK cellsanti-CD-3-MUC1 bispecific antibody-armed CIK cellsanti-CD 3-MUC1 bispecific antibody-armed CIK cells
02
Targets
CD3 (T-cell surface glycoprotein CD3)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on Activated CIK + CD3-MUC1 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Activated CIK + CD3-MUC1 bispecific antibody.